Ying Huang, Legend CEO
November 18, 2022 03:08 PM EST
China
Cell/Gene Tx

Leg­end CEO spells out path to $5B in sales for mul­ti­ple myelo­ma CAR-T ther­a­py Carvyk­ti

Zachary Brennan

Senior Editor

Ap­proved in Feb­ru­ary as a fifth-line treat­ment for adults with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma, J&J and Leg­end’s CAR-T ther­a­py Carvyk­ti may not have start­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times